WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC codes 2020

ATC codeATC level name
A02BC08vonoprazan
A02BD12rabeprazole, amoxicillin and clarithromycin
A02BD13rabeprazole, amoxicillin and metronidazole
A02BD14vonoprazan, amoxicillin and clarithromycin
A02BD15vonoprazan, amoxicillin and metronidazole
A03BB06homatropine methylbromide
A03FA09 mosapride
A07AA13rifamycin
A10BK06sotagliflozin
A16AB19pegvaliase
B01AF04betrixaban
B02AB05ulinastatin
B03AA12ferrous sodium citrate
B03XA06luspatercept
B06AX 1)Other hematological agents
B06AX01crizanlizumab
C08CA51amlodipine and celecoxib
C09BX04perindopril, bisoprolol and amlodipine
C09DB09fimasartan and amlodipine
C09DX07irbesartan, amlodipine and hydrochlorothiazide
C10AX15bempedoic acid
C10BA07rosuvastatin and omega-3 fatty acids
C10BA08atorvastatin and omega-3 fatty acids
C10BA09rosuvastatin and fenofibrate
C10BX16rosuvastatin and fimasartan
C10BX17rosuvastatin and ramipril
D03AX14Centella asiatica herba
D06AX15rifamycin
D11AA01glycopyrronium
G01AF55econazole, combinations
G04CA54tamsulosin and tadalafil
H01CC03elagolix
H02CA02osilodrostat
J01AA14sarecycline
J01AA15omadacycline
J01GB14plazomicin
J01XX12lefamulin
J04AB06enviomycin
J05AH04laninamivir
J05AP10elbasvir
J05AP11grazoprevir
J05AP58daclatasvir, asunaprevir and beclabuvir
J05AR25lamivudine and dolutegravir
J05AR26darunavir and ritonavir
J05AR27lamivudine, tenofovir disoproxil and dolutegravir
J05AX24tecovirimat
J05AX25baloxavir marboxil
J05AX26amenamevir
J05AX27favipiravir
L01XC33cemiplimab
L01XE51acalabrutinib
L01XE52quizartinib
L01XE53larotrectinib
L01XE54gilteritinib
L01XE56entrectinib
L01XE57fedratinib
L01XX62ivosidenib
L01XX63glasdegib
L01XX64entinostat
L01XX65alpelisib
L01XX66selinexor
L01XX67tagraxofusp
L01XX68belotecan
L02BB06darolutamide
L03AX21elapegademase
L04AA41imlifidase
L04AA42siponimod
L04AA43ravulizumab
L04AA44upadacitinib
L04AB07opinercept
L04AC18risankizumab
L04AX08darvadstrocel
N02CD03fremanezumab
N05CD14remimazolam
N06AX27esketamine 2)
N06BA14solriamfetol
N07XX15inotersen
P01BA07tafenoquine
P02CX03moxidectin
R03AK14indacaterol and mometasone
R03AL10formoterol and tiotropium bromide
R03AL11formoterol, glycopyrronium bromide and budesonide
R03AL12indacaterol, glycopyrronium bromide and mometasone
R03BB08revefenacin
S01AA28vancomycin
S01EE06 latanoprostene bunod
S01EE51latanoprost and netarsudil
S01LA06brolucizumab
S01XA27voretigene neparvovec
V03AF11arginine and lysine
V04CX02folic acid
V04CX03methacholine
V04CX04mannitol
V04CX0513C-urea
V04CX06hexaminolevulinate
V04CX07edrophonium
V04CX08carbon monoxide
V04CX09patent blue
V09IX13methionine (11C)
1) New 4th level
2) Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14.

Last updated: 2019-12-20